UNITED STATES SECURITIES AND EXCHANGE COMMISSION February 15, 2019

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

AMAG Pharmaceuticals, Inc.

File No. 1-10865 - CF#36589

AMAG Pharmaceuticals, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on August 3, 2018, as amended on December 21, 2018.

Based on representations by AMAG Pharmaceuticals, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.7 through December 20, 2027 Exhibit 10.8 through June 4, 2028

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields Secretary